Dept. of Surgery, Máxima Medical Centre, Veldhoven, The Netherlands.
Dept. of Surgery, Máxima Medical Centre, Veldhoven, The Netherlands.
Eur J Vasc Endovasc Surg. 2018 Jun;55(6):874-881. doi: 10.1016/j.ejvs.2018.03.014. Epub 2018 Apr 19.
Upper arm arteriovenous fistulas (AVF) occasionally develop high flow. Revision using distal inflow (RUDI) effectively reduces flow of high flow accesses (HFA) in the short-term and is also popularised for treatment of haemodialysis access induced distal ischaemia (HAIDI). The long-term efficacy is unknown. The study's aim was to report on 3 year RUDI patency and recurrence rates for HFA with and without HAIDI.
This was a retrospective cohort study of patients with a HFA with or without HAIDI undergoing RUDI using greater saphenous vein (GSV) interposition between March 2011 and October 2017 at three facilities. AVFs were termed HFA if flow volumes exceeded 2 L/min on two consecutive measurements using dilution techniques. HAIDI was diagnosed as recommended. Following RUDI, follow up was not different from standard care in AVF patients. Data on post-operative flows and re-interventions were extracted from electronic patient files. Loss to follow up was avoided. Rates of patency and HFA recurrence were analysed.
During the observation period, 21 patients were studied (7 females, 54 years ± 3). Fourteen had uncomplicated HFA whereas seven had additional HAIDI. Immediately post-operatively, flows decreased threefold (3120 mL/min ± 171 vs. 1170 mL/min ± 87, p < .001). Overall 3 year primary patency was 48% ± 12 (HFA, 55% ± 15 vs. HAIDI/HFA, 29% ± 17, p = .042). Secondary patency was identical in both groups (overall, 84% ± 9). Interventions were percutaneous transluminal angioplasty (n = 12, 9 patients), thrombectomy (n = 7, 3 patients), and revision with new interposition grafts (n = 3). After 3 years, 51% ± 12 were free of high flow (HFA, 32% ± 13 vs. HAIDI/HFA, 100%, p = .018). High immediate post-operative access flow predicted recurrence (OR 1.004 [1.000-1.007], p = .044). Patients with recurrence were 12 years younger than those without (p = .055).
RUDI with GSV interposition for HFA offers acceptable patency rates after 3 years although re-interventions are often required. High immediate post-operative flows and young age are associated with recurrent high flow.
上臂动静脉瘘(AVF)偶尔会出现高流量。使用远端流入(RUDI)进行修正可有效降低高流量通路(HFA)的流量,并且也因其可治疗血液透析通路引起的远端缺血(HAIDI)而受到广泛应用。但长期疗效尚不清楚。本研究旨在报告 HFA 伴或不伴 HAIDI 患者接受 RUDI 治疗后 3 年的通畅率和复发率。
这是一项回顾性队列研究,纳入 2011 年 3 月至 2017 年 10 月期间在三个中心因 HFA 伴或不伴 HAIDI 而行 RUDI 治疗的患者,使用大隐静脉(GSV)间置。如果通过稀释技术连续两次测量流量超过 2L/min,则将 AVF 称为 HFA。HAIDI 按照推荐的标准进行诊断。RUDI 后,随访与 AVF 患者的标准治疗相同。从电子患者档案中提取术后流量和再干预的数据。避免了失访。分析通畅率和 HFA 复发率。
在观察期间,共有 21 名患者(7 名女性,年龄 54 岁±3 岁)入组。14 例为单纯 HFA,7 例为 HFA 合并 HAIDI。术后即刻,流量减少三倍(3120ml/min±171 比 1170ml/min±87,p<0.001)。总体 3 年一期通畅率为 48%±12(HFA 为 55%±15,HAIDI/HFA 为 29%±17,p=0.042)。两组的二期通畅率相同(总体为 84%±9)。介入治疗包括经皮腔内血管成形术(n=12,9 例患者)、血栓切除术(n=7,3 例患者)和使用新的间置移植物进行修正(n=3)。3 年后,51%±12 例患者无高流量(HFA 为 32%±13,HAIDI/HFA 为 100%,p=0.018)。高术后即刻通路流量预示着复发(OR 1.004[1.000-1.007],p=0.044)。复发患者比未复发患者年轻 12 岁(p=0.055)。
使用 GSV 间置进行 RUDI 治疗 HFA,3 年后的通畅率可接受,但往往需要再次介入治疗。高术后即刻流量和年轻与复发性高流量有关。